Webcasts

Process Design of a Two-Step mAb Purification Using a Multi-Column Continuous Chromatography Platform

October 18, 2022, 2pm EDT
Evotec recently hosted its Innovation Week webinar series - 5 virtual sessions over 5 days. Session 5 discusses Evotec’s capabilities for supporting all activities across the R&D continuum for biotherapeutics, i.e. Discovery and optimization of novel antibodies for specific disease targets, evaluation of lead antibodies for disease efficacy and safety, alongside process development and manufacturing

Translate your idea into product: AI-driven antibody discovery at Evotec

Tuesday, October 11, 2022 at 11 AM EDT
Learn about best practices in Host Cell Protein (HCP) assay development and qualification. Improve your understanding of the advanced orthogonal methods used to fully characterize HCPs in your process

Best Practices in HCP Assay Development and Integration of Advanced Orthogonal Methods

Thursday, September 29, 2022 at 7am PT | 10am ET | 4pm CET 

Novel methods have been developed and applied on Biotherapeutics Beasts in the half Megadalton to 3-4 MDa range to measure AAV Full:Empty genome ratio using charge detection mass spectrometry on the Q Exactive UHMR mass spectrometer with Direct Mass Technology mode. 

Characterization of Biotherapeutic Beasts by Mass Spectrometry

Wednesday, September 28, 2022 at 10 AM EST | 4 PM CET

Optimize your late-phase strategy to prepare your biologic for commercialization. CDMO experts share their time-tested best practices on how to adapt for uncertain market demand to get your drug to market on time.  

Preparing biologics for commercialization: strategies to reduce risk and optimize outcomes

Tue, Sep 27, 2022 2:00 PM EDT | 11am PT | 2pm ET | 7pm BST
Many novel cell and gene therapies (CGTs) are now entering the commercialization stage but, as developers look to recoup investment and quickly deliver life-saving therapies to the patients that need them, they face a myriad of challenges. In this webinar, learn how advanced therapy medicinal product (ATMP) platforms, using single-use systems, are delivering streamlined, efficient and cost-effective manufacturing solutions in this dynamic sector.

On the Brink of Commercialization: How do we bring ground-breaking cell and gene therapies to market faster?

Tue, Sep 27, 2022 11:00 AM EDT
Learn how Karl Mechtler has developed an end-to-end workflow to efficiently prepare and analyze samples for single-cell proteomics by mass spectrometry. This workflow enables direct injection of single cells to identify approximately 1,500 protein groups per analytical run and uncover the surprising heterogeneity of cell populations. 

New Developments in Mass Spectrometry-Based Single-Cell Proteomics

Thursday, September 22nd, 2022 
9:00am EDT|6:00am PDT|2:00pm BST|3:00pm CEST
2:00pm EDT|11:00am PDT|7:00pm BST|8:00pm CEST
See how RapidFire automated size exclusion chromatography (SEC) combined with the power of ion mobility mass spectrometry (IM-MS) enables efficient biotherapeutic development.

Automated High Throughput SEC Native Mass Spectrometry for mAb Screening

Wed, Sep 21, 2022 2:00 PM EDT
This webinar will review the key considerations and gaps in evaluating freeze/thaw solutions, examine the elements of a dedicated technology center to bridging these gaps and development risks, and explore successful case studies of a technology center optimizing processes and speed-to-market.

Advantages of a One-Stop Shop for Freeze/Thaw And Cold-Chain Process Development

Thursday, September 15th, 2022 at 4pm CEST | 3pm BST | 10am EDT Extra cellular vesicles and especially exosomes have recently gained favor for therapeutic medicine development due to possessing structures that can be modified to conveniently deliver payloads, such as specific proteins, genetic lipids, and genetic materials including messenger RNA (mRNA, and genomic DNA (gDNA) from their progenitor cell. Most recently, there is increasing interest in the therapeutic potential of exosomes produced by Mesenchymal Stem Cells (MSCs). Stirred-tank bioreactors offer the possibility to tightly control and monitor the production of exosomes, as well as the scalability, to produce increasing amounts. However, the cultivation of stem cells in stirred-tank bioreactors requires profound knowledge and precise control of the process.